Evaluation of lipoprotein(a) — a novel cardiovascular risk factor in patients with atherosclerotic cardiovascular diseases receiving PCSK9-targeted therapy in Russian real-world practice

Aim. To evaluate the effect of PCSK9-targeted therapy on lipoprotein(a) (Lp(a)) levels in patients with atherosclerotic cardiovascular diseases who have not achieved the target low-density lipoprotein cholesterol (LDL-C) level (statins at maximum tolerated doses and/or ezetimibe).Material and method...

Descrizione completa

Dettagli Bibliografici

Autori principali:	A. I. Sapina, Yu. Yu. Varlamova, M. G. Papyrina, A. S. Bezymyannyy, E. L. Kordzaya, E. Yu. Vasilyeva
Natura:	Artigo
Lingua:	Russo
Pubblicazione:	«FIRMA «SILICEA» LLC 2025-01-01
Serie:	Российский кардиологический журнал
Soggetti:	lipoprotein(a) atherosclerotic cardiovascular diseases inclisiran
Accesso online:	https://russjcardiol.elpub.ru/jour/article/view/6177
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!